“This is absurd.
She was being reassigned.”
I recognized the sharpness in his voice.
He was used to controlling rooms by speaking first and longest.
The attorney did not react.
“Ms.
Vance, were you informed of a reassignment?”
“No.
My father told me I was ‘just the mechanic,’ said mechanics didn’t get equity, threatened to withhold severance, and told me to smile.”
Nobody spoke for several seconds.
I wondered how many of the people in the auditorium had heard him whisper it.
Then another voice entered the call.
One of the FDA observers.
“Ms.
Vance, after termination, did you receive the routine supervisory safety attestation?”
“Yes.”
“What response did you enter?”
“DECLINE.”
“Why?”
“Because the company had removed its designated supervisor while continuing to represent the platform as ready for operational transfer.
Accepting would have certified something that was no longer true.”
“Did you initiate any malicious shutdown, delete data, alter patient devices, or interfere with existing clinical operation?”
“No.”
That question mattered.
My father had already started telling people I had sabotaged the company.
The observer continued.
“What happens after a decline?”
“New activations, safety-critical updates, remote calibration changes, and operational transfer are suspended until supervised review.
Existing approved patient operation continues under its last validated configuration.”
“And can an executive override that state with a password?”
“No.”
From somewhere near the conference phone, Brent muttered something.
The attorney asked the obvious question.
“Why not?”
“Because executives are among the people the control is designed to restrain.”
That ended the argument about the password.
It did not end the disaster.
The acquisition team requested the personnel records supporting Brent’s announced role.
Then they requested the engineering authorship logs.
Then the regulatory submissions.
Then the design-history file.
My father had built the entire presentation around one claim: Brent was the brilliant creator of Aries, the natural successor, the technical visionary who would lead the platform after the sale.
The documents told another story.
My name appeared everywhere.
Architecture approvals.
Failure analyses.
Risk controls.
Clinical integration reviews.
Regulatory responses.
Thousands of code commits.
Ten years of work left a trail no stage lighting could erase.
Brent’s trail was smaller.
Much smaller.
He had attended executive meetings, entertained investors, traveled to conferences, and presented polished summaries produced by other people.
His technical contribution to the safety architecture was almost nonexistent.
That would have been embarrassing by itself.
